The CDC warns about the mosquito-borne chikungunya virus, which is gaining prevalence in South Asia and Europe, and affecting ...

What if the next global health upheaval isn’t a new flu or an unknown virus, but something that has been buzzing along in the background for years literally? As chikungunya infections climb to record ...

The European Union’s health regulator has lifted the temporary restriction on the use of French drugmaker Valneva’s chikungunya vaccine, Ixchiq, in adults aged 65 and above, following a safety review.

News Peg. The FDA said it had approved the first chikungunya vaccine for use in adults ages 18 and older who are at high risk of catching the virus. Peter Marks, director of the FDA’s Center for ...

In the first quarter of 2025, Ixchiq sales increased to 3 million euros from 0.2 million euros a year ago.. Sales include a very small number of the 40,000 doses Valneva supplied to La Réunion to ...

Just as new outbreaks of chikungunya threaten to become another epidemic, Bavarian Nordic, maker of a vaccine against the ...

The Food and Drug Administration (FDA) has granted accelerated approval to Ixchiq as the first chikungunya vaccine for individuals 18 years of age and older who are at increased risk of exposure ...

With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU ...

In addition to Brazil, IXCHIQ ® is approved for the prevention of disease caused by the chikungunya virus in people aged 12 years and older in the EU, and in people aged 18 years and older in the ...

Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted: Amsterdam, The Netherlands Monday, July 14, 2025, 12:00 Hrs [IST] EMA’s safety committee (PR ...

Saint-Herblain (France), March 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine ...